Literature DB >> 34347280

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis.

Robert K Shin1, Kottil W Rammohan2, Mitzi J Williams3.   

Abstract

Entities:  

Keywords:  B-cell-targeting therapy; COVID-19; Coronavirus; Disease modifying therapy; Multiple sclerosis; Patient education; SARS-CoV-2; Vaccines

Year:  2021        PMID： 34347280     DOI： 10.1007/s40120-021-00266-z

Source DB:  PubMed          Journal:  Neurol Ther        ISSN： 2193-6536


× No keyword cloud information.
  3 in total

1.  Burton's Agammaglobulinemia and COVID-19.

Authors:  Justin G Hovey; Denise Tolbert; Druhan Howell
Journal:  Cureus       Date:  2020-11-25

2.  Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.

Authors:  Sadia Waheed; Angel Bayas; Fawzi Hindi; Zufe Rizvi; Patricio S Espinosa
Journal:  Cureus       Date:  2021-02-18

3.  Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Authors:  Anat Achiron; Mathilda Mandel; Sapir Dreyer-Alster; Gil Harari; David Magalashvili; Polina Sonis; Mark Dolev; Shay Menascu; Shlomo Flechter; Rina Falb; Michael Gurevich
Journal:  Ther Adv Neurol Disord       Date:  2021-04-22       Impact factor: 6.570
  3 in total
  3 in total

Review 1.  Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.

Authors:  Elisabetta Meacci; Federica Pierucci; Mercedes Garcia-Gil
Journal:  Biomedicines       Date:  2022-05-04

Review 2.  Ocrelizumab: A Review in Multiple Sclerosis.

Authors:  Yvette N Lamb
Journal:  Drugs       Date:  2022-02-22       Impact factor: 11.431

3.  Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19.

Authors:  Robert K Shin; Pavle Repovic; Joseph R Berger
Journal:  Neurol Ther       Date:  2022-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.